Selank / Semax is a research-community pairing of two separately registered Russian nootropic nasal drops built from the same Pro-Gly-Pro extension chemistry, Semax from a fragment of ACTH and Selank from the immune peptide tuftsin. No manufacturer combines them, and no study, in any species, has tested them administered together. Each compound has its own separate, and very different, evidence base: Semax has real if methodologically limited human stroke-rehabilitation trials, while Selank, in the search run for this site, has no human trial at all, only rat and mouse pharmacology.
Ask about Selank + Semax combination
Research snapshot
| Peptide category | Research-community pairing of two separately registered Russian nootropic nasal drops (not a manufacturer combination) |
| Primary research interest | Cognitive/neuroprotective support (Semax) paired with anxiolytic/calming effect (Selank) |
| Highest available evidence | Semax: Tier 2 (non-blinded human post-stroke rehabilitation trials). Selank: Tier 3 (animal only, no human trial located) |
| Human research available | Semax: yes, limited. Selank: no. The combination: no study of the pair exists in any species |
| Development status | Not a formulated combination drug product; a research-community stacking practice |
| Regulatory status | Both individually registered as prescription drugs in Russia only; no fixed combination is registered anywhere |
Technical identity (composition)
| Primary name | Selank / Semax stack (research-community name) |
| Composition | Semax (ACTH-fragment-derived Pro-Gly-Pro-extended peptide) + Selank (tuftsin-derived Pro-Gly-Pro-extended peptide) |
| Share of vial by mass | Not standardised: sold as two separate nasal-drop solutions, dosed independently, not co-formulated |
| Peptide sequence | Not applicable at the combination level; see individual Selank and Semax pages for each molecule’s sequence |
| Molecular formula | Not applicable: a two-product stacking practice, not a single molecular entity |
| CAS Registry Number | Not applicable: no CAS number is assigned to the combination itself |
| Chemical modifications | Not applicable at the combination level; see individual component pages |
| Developer or originator | Not applicable: a research-community pairing, not a developed combination product |
| Development status | Not in formal development; no INN, no approved combination status |
What it is
Selank / Semax is a name applied to combining two separately registered Russian nootropic drugs, sold as intranasal drops, in the same research-peptide routine. Both were developed from the same Pro-Gly-Pro-tripeptide-extension approach at Russian institutes: Semax extends a fragment of ACTH, Selank extends the immune peptide tuftsin. They are not co-formulated in a single Russian pharmaceutical product; each is its own registered drug, and “stacking” them is a research-community practice, not a manufacturer’s combination product.
Potential benefits and research applications
Cognitive and neuroprotective support, carried entirely by Semax’s own separate record
The cognitive rationale for this stack rests on Semax’s post-stroke rehabilitation trials, which reported improved functional recovery and higher plasma BDNF. Those trials studied Semax alone, in stroke patients, not in combination with Selank, and not in healthy people seeking cognitive enhancement.
Evidence: has been reported anecdotally for the combination; the underlying human evidence (Tier 2, non-blinded human trials) belongs to Semax alone, not to the pair.
Anxiolytic and calming effect, carried entirely by Selank’s rodent-only record
The calming rationale for this stack rests on Selank’s rat anxiety-model findings. No human trial of Selank, alone or combined, was located for this site, so this half of the stack’s rationale rests entirely on animal data.
Evidence: is being investigated at the animal level only (Tier 3, published animal evidence, Selank alone); has not been established in any human, combined or otherwise.
What is known about the combination
No study, animal or human, testing Selank and Semax administered together was located for this entry. Each has its own separate entry on this site, and each has its own separate, and very different, evidence base: Semax has real, if methodologically limited, published human trials in post-stroke rehabilitation; Selank, on the search run for this entry, has no published human trial of any kind, only rat and mouse pharmacology.
The rationale usually offered for combining them, that Semax contributes cognitive and neuroprotective effects while Selank contributes anxiolytic and calming effects, is a plausibility argument built from each compound’s own separate literature, not a tested claim about the pair.
What the component evidence actually says
Both share on this site are worth reading before this pairing makes sense. In brief:
- Semax’s human evidence is limited to post-stroke rehabilitation trials that were not blinded, placebo-controlled studies by Western standards, and none has been independently replicated outside Russia.
- Selank has no human trial located in the search run for this site’s entry on it at all; every published finding is in rats or mice.
Stacking a compound with limited human evidence together with a compound that has none does not average out to something in between. It combines two separate sets of open questions.
What is not known
Whether combining the two produces any effect, in any direction, that either alone would not. No study of the pair exists.
Whether the two are chemically compatible when mixed in the same nasal-drop solution outside their separate, manufacturer-controlled formulations. No stability data for a mixed solution was located.
Everything already unknown about each component separately, including whether Selank’s effects, entirely rodent so far, translate to a human being at all.
What dosage information circulates?
Figures in this section summarize amounts and schedules reported in published research or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate.
| Reported use or research objective | Route reported | Amount reported | Frequency reported | Reported duration | Evidence or source category |
| Cognitive and calming stack, general | Intranasal | Component doses as described on each compound’s own entry (no combined-product dose is proposed) | 1–3 times daily | Often cycled, days to a few weeks | Community/vendor reported |
No established or reliably sourced dosing information for the combination was identified, no study of Selank and Semax administered together, in any species, was located. Circulating material generally directs the reader to each component’s own separate dosing figures rather than proposing a combined-product dose, consistent with these being two separately manufactured drugs rather than one blended product. See each compound’s own entry for how its circulating figure compares to its own studied record, for Semax that record is post-stroke rehabilitation at doses well above the circulating cognitive-use figure, and for Selank there is no human studied record to compare against at all.
Regulatory status
Both Semax and Selank are registered prescription drugs in Russia individually. Neither is approved in the United States, the European Union or any other major jurisdiction, and no fixed combination product of the two is registered anywhere in the sources reviewed for this entry.
Frequently asked questions
What is the Selank / Semax stack?
It is a research-community practice of using two separately registered Russian nootropic nasal drops together, Semax and Selank, not a manufacturer’s combination product.
How does the Selank / Semax combination work?
There is no mechanism study of the pair. Each compound’s own proposed mechanism, from its own separate literature, is described on its own entry.
What dosage has been studied for the combination?
No established or reliably sourced dosing information for the combination was identified. No study of Selank and Semax administered together, in any species, was located.
What dosage commonly circulates online for this stack?
Circulating material generally points to each compound’s own separate dosing figures rather than proposing a combined-product dose. See each compound’s own entry for its circulating figure.
Has the combination been studied in humans?
No. No study of Selank and Semax administered together was located for this entry, in any species.
Is this combination approved for use?
No. Each component is individually registered as a prescription drug in Russia, but no fixed combination product is registered anywhere.
What routes of administration are reported?
Both components are used intranasally as separate nasal-drop solutions.
Does this stack work better than either compound alone?
This has not been established. No study has tested the two together, so any claimed synergy is a plausibility argument built from each compound’s separate literature, not a tested finding.
What side effects have been reported?
No safety data specific to the combination exists. Each compound’s own side-effect profile, described on its own entry, is the only available information.
What remains unknown about the Selank / Semax stack?
Whether combining the two produces any effect that either alone would not; whether the two are chemically compatible mixed together outside their separate formulations; and everything already unknown about each component separately, including whether Selank’s entirely rodent evidence base translates to humans at all.
Bottom line
Selank / Semax is a plausibility-driven research-community stack, not a studied combination. Semax brings real, if methodologically limited, human stroke-rehabilitation data; Selank brings none at all, only rat and mouse pharmacology. Combining a compound with limited human evidence with one that has no human evidence does not average into something in between; it simply stacks two separate sets of open questions, and no study of the pair, in any species, exists to resolve them.
What circulates E5
| Reported use | Route | Amount reported | Frequency | Reported length |
|---|---|---|---|---|
| Cognitive and calming stack, general | Intranasal | See each component's own entry | One to three times daily | Often cycled, days to a few weeks |
Circulating material for this stack generally directs the reader to each component's own separate dosing figures rather than proposing a combined-product dose, consistent with the fact that these are two separately manufactured drugs, not one blended product. See each compound's own entry for the comparison between its circulating figure and its own studied record; for Semax that record is post-stroke rehabilitation at doses far above the circulating cognitive-use figure, and for Selank there is no human studied record to compare against at all.
Recorded as an observation about what is published elsewhere. No figure here is a dose, a protocol, or a recommendation, and nothing in this section is evidence that any amount is safe or effective.
Research area: Neuro and cognitive.